JP2013542930A5 - - Google Patents

Download PDF

Info

Publication number
JP2013542930A5
JP2013542930A5 JP2013531721A JP2013531721A JP2013542930A5 JP 2013542930 A5 JP2013542930 A5 JP 2013542930A5 JP 2013531721 A JP2013531721 A JP 2013531721A JP 2013531721 A JP2013531721 A JP 2013531721A JP 2013542930 A5 JP2013542930 A5 JP 2013542930A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
topical pharmaceutical
acceptable salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013531721A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542930A (ja
Filing date
Publication date
Priority claimed from US13/232,139 external-priority patent/US20120076738A1/en
Application filed filed Critical
Publication of JP2013542930A publication Critical patent/JP2013542930A/ja
Publication of JP2013542930A5 publication Critical patent/JP2013542930A5/ja
Pending legal-status Critical Current

Links

JP2013531721A 2010-09-28 2011-09-27 皮膚科疾患の併用による治療 Pending JP2013542930A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38726810P 2010-09-28 2010-09-28
US61/387,268 2010-09-28
US13/232,139 US20120076738A1 (en) 2010-09-28 2011-09-14 Combination treatment for dermatological conditions
US13/232,139 2011-09-14
PCT/US2011/053455 WO2012050831A2 (en) 2010-09-28 2011-09-27 Combination treatment for dermatological conditions

Publications (2)

Publication Number Publication Date
JP2013542930A JP2013542930A (ja) 2013-11-28
JP2013542930A5 true JP2013542930A5 (enExample) 2014-09-18

Family

ID=45870879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013531721A Pending JP2013542930A (ja) 2010-09-28 2011-09-27 皮膚科疾患の併用による治療

Country Status (10)

Country Link
US (3) US20120076738A1 (enExample)
EP (1) EP2621498A4 (enExample)
JP (1) JP2013542930A (enExample)
KR (1) KR20140056129A (enExample)
CN (1) CN103354744A (enExample)
AU (1) AU2011314151A1 (enExample)
CA (1) CA2821993A1 (enExample)
MX (1) MX2013003639A (enExample)
RU (1) RU2013113188A (enExample)
WO (1) WO2012050831A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130079312A1 (en) * 2011-09-28 2013-03-28 Elorac, Ltd. Method of Treating Hair Loss Due to Systemic Chemotherapy
AU2014262960A1 (en) * 2013-05-06 2015-11-26 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
US20150258011A1 (en) * 2014-03-15 2015-09-17 Marty Richard Hunter Treatment of keratinized tissues
AU2016222902A1 (en) * 2015-02-24 2017-08-31 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
JP6659819B2 (ja) * 2015-07-09 2020-03-04 ガルデルマ・ソシエテ・アノニム 化学療法に関連する脱毛の軽減方法
RU2605687C1 (ru) * 2015-09-21 2016-12-27 Ирина Николаевна Усманова Способ лечения рецидивирующего афтозного стоматита
WO2018212846A1 (en) 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
EP3784260A4 (en) * 2018-04-18 2022-03-09 Forte Subsidiary, Inc. Compositions for the treatment of skin conditions
BR112021003452A2 (pt) * 2018-08-29 2021-05-18 Cellix Bio Private Limited composto e composição farmacêutica
WO2020065085A1 (fr) * 2018-09-28 2020-04-02 Galderma Research & Development Composition pharmaceutique comprenant de la brimonidine, et ses utilisations
SG11202106716RA (en) * 2019-01-12 2021-07-29 Cellix Bio Private Ltd Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof
US20220211672A1 (en) * 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
BR112021020962A2 (pt) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Métodos de tratamento de prurido

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
CA2567401C (en) * 2004-05-25 2013-11-12 Sansrosa Pharmaceutical Development, Inc. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
SI2182960T1 (sl) * 2007-07-27 2014-07-31 Galderma Laboratories Inc. Spojine, formulacije in postopki za zmanjĺ anje koĺ˝nih gub, meäśkanja in poveĺ anja
EP2818184B1 (en) * 2007-11-16 2018-10-31 Allergan, Inc. Compositions and methods for treating Purpura
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
AU2011273509A1 (en) * 2010-06-30 2013-06-13 Galderma Research & Development Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
BR112014009210A2 (pt) * 2011-10-19 2017-04-18 Galderma Sa método para a redução da vermelhidão facial cutânea

Similar Documents

Publication Publication Date Title
JP2013542930A5 (enExample)
RU2013113188A (ru) Комбинированное лечение дерматологических состояний
JP2013538853A5 (enExample)
JP2017537936A5 (enExample)
JP2013511534A5 (enExample)
BR112014009927A2 (pt) "derivado de azol, composição farmacêutica que o compreende e uso do mesmo"
CY1117183T1 (el) Διακλαδισμενα παραγωγα 3-φαινυλοπροπιονικου οξεος και η χρηση τους
JP2014505733A5 (enExample)
BR112015012565A2 (pt) composto, composição cosmética ou farmacêutica, e, uso de um composto
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
CO6640250A2 (es) Formulación tópica que comprende (r)-3-ciclopentil-3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo o una sal farmaceúticamente aceptable del mismo y una emulsión de aceite en agua
JP2013522184A5 (enExample)
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
WO2012143576A3 (en) Compounds for preventing, reducing and/or alleviating itchy skin condition(s)
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
JP2014511393A5 (enExample)
NZ594184A (en) Skin treatment
MX2015013148A (es) Nuevos compuestos de bencensulfonamida, metodo para sintetizar los mismos, y uso de los mismos en medicina asi como tambien en cosmeticos.
JP2018522875A5 (enExample)
WO2013022243A3 (ko) 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
SA519410993B1 (ar) النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية
BR112013007389A2 (pt) derivado de 1,2,4-triazolona.
EA201590546A1 (ru) Способы лечения заболеваний, связанных с волосами
BR112015027436A8 (pt) composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos
MX2014014818A (es) Composicion farmaceutica para el tratamiento de enfermedades inflamatorias de la piel.